Sign Up
Stories
Cervical Cancer Vaccine Supply Boosted
Share
Advancements in Antibodies to Protect Im...
COVID-19 Impact on Immunocompromised Pat...
COVID-19 Protection Advancements
China Vaccinates Against XBB Variant
European Vaccine Safety Skepticism
Global Interferon Market Analysis
Overview
API
Serum Institute of India is ramping up the supply of its HPV vaccine ahead of a cervical cancer immunization campaign. The CEO expects the vaccine to be part of the government program soon, with plans to offer affordable rates and distribute 50 million doses to girls aged 9-14. Additionally, the company is gearing up to export the vaccine globally in 2026.
Ask a question
How might the increased availability and affordability of the HPV vaccine impact cervical cancer rates in India?
What are the broader implications of government-supported immunization campaigns for public health outcomes?
What challenges could Serum Institute face in scaling up production to meet the global demand for the vaccine in 2026?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage
ndtv.